Duchenne Muscular Dystrophy: The Race For The $1bn Opportunity

 
• By Lucie Ellis-Taitt and Eleanor Malone

With three products now approved in Europe and/or the US for Duchenne Muscular Dystrophy, an FDA decision pending on PCT Therapeutics' ataluren and multiple companies exploring different approaches in preclinical and clinical studies, Scrip provides an overview of the development landscape and commercial results to date.

Abstract mash line and point magnifying glass on white background with an inscription. Starry sky or space, consisting of stars and the universe. Vector business illustration
Investigating DMD: Drug Sales, Deals and Data • Source: Shutterstock

More from Rare Diseases

More from Scrip